Salute e Benessere

AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs…

LONDON and PHOENIX, April04, 2025(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature Classifier (MSC) blood test for use in the more than 1.6 million US patients diagnosed each year with nodules as part of current lung cancer screening protocols. The company believes it will be able to further expand the use of the test to all...
Nasdaq GlobeNewswire
04/04/2025

Nature's Best Experts Reveal 6 Underrated Nutrients for Stronger Bones - Beyond…

Nature's Best, a leading UK vitamin and supplement brand, reveals six crucial elements beyond calcium that can help support your bones: Nature's Best, a leading UK vitamin and supplement brand, reveals six crucial elements beyond calcium that can help support your bones: Pauline Peh, Brand Lead of Nature's Best, said:"We all know how essential calcium is for our bones; however, it is important to remember that calcium alone is not enough to maintain bone health. "Research and...
PR Newswire
04/04/2025

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting

"We are excited to share data validating NeuLogiq Platform cognitive tasks to measure memory, executive function and psychomotor function in broader neurodegenerative indications. We also demonstrated sensitivity to underlying Alzheimer's pathology, correlating to plasma ptau217 status," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated…
PR Newswire
04/04/2025

Lundbeck to present positive pipeline data at American Academy of Neurology…

"DEEs can be caused by a range of acquired, syndromal, and genetic etiologies, with more than 900 genes implicated. However, only a few subtypes currently have approved therapies, leaving many patients in need. The DEE-inclusive PACIFIC trial and six-month OLE data indicate that bexicaserin may be able to help address this unmet need across multiple DEE types, and highlights Lundbeck's expanding commitment to the neuro-rare space. We look forward to engaging with the global neuroscience…
PR Newswire
04/04/2025

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025

Oslo, April 04, 2025, the Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 14:00 CET on April 29, 2025. The General Meeting will be held electronically. For participation, please log in athttps://dnb.lumiagm.com/171610773. All documents regarding the Annual General Meeting are available at the Company's website: www.zelluna.comFor further information, please contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASA Email:at@radforsk...
Nasdaq GlobeNewswire
04/04/2025

IBA to share long-term growth strategy at upcoming 2025 Capital Markets Day

Louvain-la-Neuve, Belgium, 04 April, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will be hosting a Capital Markets Day (CMD) this coming Monday 7 April from 2pm to 5:00pm CEST (8am ET to 11:00am ET) at its headquarters in Louvain-la-Neuve, Belgium, and via live webcast.At the event IBA's management team will outline the company's strategic roadmap and long-term growth ambitions. The agenda is outlined below:Webcast open:...
Nasdaq GlobeNewswire
04/04/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,467,152,142 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
03/04/2025

Hop into Creativity with xTool This Easter - Unleash DIY Magic for Your Home &…

Beyond Machines: Materials & Mastery Beyond Machines: Materials & Mastery This Easter, xTool sparks your creativity with an extensive selection ofcraft-ready materials, including plywood, acrylic sheets, metal blanks, leather tags, and rainbow vinyl. These high-quality materials are crafted to inspire your imagination and deliver flawless results. For step-by-step inspiration, explore the DesignFind , which offers carefully curated guides to make your projects effortless...
PR Newswire
03/04/2025

EssilorLuxottica and Roger Federer Extend Exclusive Global Eyewear Collaboration…

EssilorLuxottica and Roger Federer Extend Exclusive Global Eyewear Collaboration Between the RF Brand and Oliver PeoplesParis, France (3 April 2025)– EssilorLuxottica and Roger Federer announce today the renewal of their successful collaboration for the design, manufacture and worldwide distribution of eyewear under the Roger Federer (“RF”) and Oliver Peoples brands. The partnership, which lives at the intersection of luxury and performance eyewear, will now extend through December 31,...
Nasdaq GlobeNewswire
03/04/2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR…

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®,a new CIS-Demasking 1cytokine bispecific technology.CLEC-1, a novel immune checkpoint target.NANTES, France – April 3, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the latest preclinical data...
Nasdaq GlobeNewswire
03/04/2025

Valneva SE Shareholding Declaration - March 2025

VALNEVADeclaration of shares and voting rightsMarch 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: April 3, 2025 Number ofsharescomposing theshare capital of ValnevaTotal numberof voting rights including suspended voting rights*Description of...
Nasdaq GlobeNewswire
03/04/2025

Resolutions from the Annual General Meeting 2025

/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2024Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.Approval of the Remuneration Report for 2024 (advisory vote)Approval of the remuneration of members of the Board of...
Nasdaq GlobeNewswire
03/04/2025

Revenue of Maxima Group in 2024 exceeds EUR 6 billion, profit down by nearly…

The Baltic retail leader MAXIMA GRUPĖ, UAB, which operates the “Maxima” retail chains in Lithuania, Latvia and Estonia, “Stokrotka“ in Poland, “T Market” in Bulgaria and the “Barbora” e-shop in the Baltic States, announces its consolidated financial results for 2024. The consolidated revenue of MAXIMA GRUPĖ grew moderately by 4.3% in 2024, reaching EUR 6.098 billion. As in recent years, the strongest revenue growth was in Poland and Bulgaria, where store expansion was most...
Nasdaq GlobeNewswire
03/04/2025

US Plasma Fractionation Market worth US$13.80 billion by 2028 with 6.4% CAGR |…

Browse in-depth TOC on "US Plasma Fractionation Market" Browse in-depth TOC on "US Plasma Fractionation Market" 150 - Tables 47 - Figures 140- Pages By Based on Product,the US plasma fractionation market is segmented into protease inhibitors, coagulation factor concentrates, immunoglobulins, albumins, and other products. Immunoglobulins accounted for the largest share of the US plasma fractionation market in 2022. The dominance of this segment is mainly attributed to the...
PR Newswire
03/04/2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at…

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys® pTau181 plasma test demonstrate potential to accurately rule out amyloid pathology, one of the hallmarks of Alzheimer's diseaseRoche will initiate a Phase III programme for trontinemab later this year based on totality of data Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were...
Nasdaq GlobeNewswire
03/04/2025

ERBC and Menarini Biotech Join Forces to Accelerate the Development of…

The partnership between ERBC and Menarini Biotech aims to lower entry barriers for early-stage innovation by offering a continuum from preclinical development to Chemistry, Manufacturing, and Controls (CMC) which includes efficient and cost-effective development strategies for biopharmaceuticals, delivery of such molecules on time, and of the required level of quality (GLP and/or GMP [1] ), support in preclinical and clinical studies, delivery of regulatory-ready data through CMC (3) and...
PR Newswire
03/04/2025

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 APRIL 2025 at 16.25 EEST Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chairman.The compositions of the Board committees were decided to be as follows:...
Nasdaq GlobeNewswire
03/04/2025

Decisions taken by Orion Corporation's Annual General Meeting on 3 April 2025

ORION CORPORATIONSTOCK EXCHANGE RELEASE – DECISIONS OF GENERAL MEETING 3 APRIL 2025 at 16.20 EEST Decisions taken by Orion Corporation's Annual General Meeting on 3 April 2025 At the Annual General Meeting of Orion Corporation held today, the following decisions were made:A dividend of EUR 1.64 per share was confirmed to be paid. The dividend is paid in two instalments. The proposals concerning the election and remuneration of the Board of Directors, the election and...
Nasdaq GlobeNewswire
03/04/2025

AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue…

Fast, Easy, Comprehensive The MosaiQ solution has been designed to provide simple workflow and fast results. Combining multiple relevant markers into one single test enables actionable insights for better patient care, as well as reducing significant hands-on time and minimizing consumable usage. For connective tissue diseases, the multiplex assay is designed to rapidly detect and identify up to 1275 disease markers per hour. Seamless, microarray-internal calibration and quality control as well…
PR Newswire
03/04/2025

Minesto announces outcome in the exercise of warrants of series TO4 and resolves…

The subscription period for exercise of the warrants of series TO4 took place during the period from and including 18 March 2025, up to and including 1 April 2025. The subscription price per share for exercising the warrants of series TO4 was determined to SEK 1.54. The subscription period for exercise of the warrants of series TO4 took place during the period from and including18 March 2025, up to and including1 April 2025. The subscription price per share for exercising the warrants of...
PR Newswire
03/04/2025

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a…

MNV-201 is Minovia's second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondriaRare Pediatric Designation grantedMNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April03, 2025(GLOBE NEWSWIRE) --Minovia Therapeutics Ltd, a clinical stage biopharmaceutical...
Nasdaq GlobeNewswire
03/04/2025

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules…

Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a new standard for the quantum of a nondilutive facility for a development-stage therapeutics company.Facility adds to the $448 million cash position disclosed in previously filed 10-K and provides funding for the next steps of the...
Nasdaq GlobeNewswire
03/04/2025

HALiXPEDITE: Transforming Biologics Therapy Development Programs with Seamless…

"Biologics-based therapies offer transformative potential for a multitude of diseases. Yet, despite their revolutionary promise, the development of these therapies is frequently impeded by substantial financial costs and production challenges, rendering their advancement to clinical readiness a significant hurdle. This contributes to the reality that many projects unfortunately do not succeed into clinical trials," notes Debby Vermeer, Alliance Management at HALIX. "This high…
PR Newswire
03/04/2025

Study Links Bacterial Load to Pain in Venous Ulcers, Demonstrating Effective…

"For years, I have noticed a trend that patients with especially painful VLUs tend to show positivity for bacterial fluorescence with technologies like MolecuLight," said Dr. Oropallo. "It is rewarding to quantify these observations and share our findings with the scientific community." "For years, I have noticed a trend that patients with especially painful VLUs tend to show positivity for bacterial fluorescence with technologies like MolecuLight," said Dr…
PR Newswire
03/04/2025
Altri  Comunicati